Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries

Haematologica

Volumn 98, Issue 10, 2013, Pages

  Pagano, Livio ^a   Cornely, Oliver A ^b,c   Busca, Alessandro ^d   Caira, Morena ^a   Cesaro, Simone ^e   Gasbarrino, Cristiana ^f   Girmenia, Corrado ^g   Heinz, Werner J ^h   Herbrecht, Raoul ⁱ   Lass Flörl, Cornelia ^j   Nosari, Annamaria ^k   Potenza, Leonardo ^l   Racil, Zdenek ^m,n   Rickerts, Volker ^o   Sheppard, Donald C ^p   Simon, Arne ^q   Ullmann, Andrew J ^h   Valentini, Caterina Giovanna ^a   Vehreschild, Jörg Janne ^b   Candoni, Anna ^r   Vehreschild, Maria J G T ^b   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g POLICLINICO UMBERTO I   (Italy)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^m UNIVERSITY HOSPITAL BRNO   (Czech Republic)

ⁿ MASARYK UNIVERSITY   (Czech Republic)

^o ROBERT KOCH INSTITUTE   (Germany)

^p MCGILL UNIVERSITY   (Canada)

^q SAARLAND UNIVERSITY   (Germany)

^r UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

Combination therapy; Hematologic malignancies; Invasive fungal infections; Lipid formulations of amphotericin B; Mucormycosis; Posaconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEFERASIROX; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; STEROID; VORICONAZOLE;

ACUTE LEUKEMIA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MUCORMYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; REGISTER; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

COMBINATION THERAPY; HEMATOLOGIC MALIGNANCIES; INVASIVE FUNGAL INFECTIONS; LIPID FORMULATIONS OF AMPHOTERICIN B; MUCORMYCOSIS; POSACONAZOLE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; MUCORMYCOSIS; REGISTRIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84884934952     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.083063     Document Type: Letter

References (13)

1. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54(1 Suppl):S35-43.
2. Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65(2):296-302.
3. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859-67.
4. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51(7):2587-90.
5. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50(6):2009-15.
6. Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother. 2008;61(3):755-7.
7. Perkhofer S, Locher M, Cuenca-Estrella M, Rüchel R, Würzner R, Dierich MP, et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother. 2008;52(7):2636-8.
8. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B. Posaconazole mono-or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother. 2009;53(2):772-5.
9. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52(10):3786-8.
10. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61-5.
11. Sun HY, Forrest G, Gupta KL, Aguado JM, Lortholary O, Julia MB, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation. 2010;90(1):85-92.
12. Ibrahim AS, Gebremariam T, French SW, Edwards JE Jr, Spellberg B. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother. 2010;65(2):289-92.
13. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, doubleblinded, placebo-controlled trial. J Antimicrob Chemother. 2012; 67(3):715-22.